Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KIF5B | P33176 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817655 | 0.87 | NPC1 (0.49) | RAB9ANPC1MAPTKMT2ATP53 | |
| SCHEMBL3821978 | 0.85 | KCNH2 (0.57) | RAB9ANPC1MAPTKMT2AS1PR1 | |
| SCHEMBL5803349 | 0.83 | NPC1 (0.69) | RAB9ANPC1MAPTKMT2ATP53 | |
| SCHEMBL1748245 | 0.82 | NPC1 (0.45) | RAB9ANPC1MAPTHDAC6KMT2A | |
| SCHEMBL6220441 | 0.81 | KDR (0.55) | RAB9ANPC1MAPTKMT2ATP53 | |
| SCHEMBL3696752 | 0.81 | KDR (0.55) | RAB9ANPC1MAPTKMT2ATP53 | |
| SCHEMBL1748093 | 0.80 | MAPT (0.61) | RAB9ANPC1MAPTHDAC6KMT2A | |
| SCHEMBL23175289 | 0.75 | MAPT (0.60) | RAB9ANPC1MAPTHDAC6KMT2A | |
| SCHEMBL4500826 | 0.72 | KDM4E (0.54) | RAB9ANPC1MAPTKMT2ATP53 | |
| SCHEMBL25788813 | 0.72 | RAB9A (0.58) | RAB9ANPC1MAPTKMT2AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | RAB9A 2517/4885NPC1 4475/4885MAPT 2567/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | RAB9A 2066/4885NPC1 187/4885MAPT 4379/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | RAB9A 2066/4885NPC1 187/4885MAPT 4379/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | RAB9A 2066/4885NPC1 187/4885MAPT 4379/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | RAB9A 2066/4885NPC1 187/4885MAPT 4379/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | RAB9A 2066/4885NPC1 187/4885MAPT 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.